
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 117
Selected: 0
NCT ID | Title | ||
---|---|---|---|
NCT01962792 | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | ||
NCT00121420 | Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases | ||
NCT05963074 | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | ||
NCT03112174 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | ||
NCT02264574 | A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | ||
NCT02309580 | Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma | ||
NCT03145480 | Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients | ||
NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | ||
NCT02956382 | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | ||
NCT00734773 | Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL | ||
NCT02943473 | Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients | ||
NCT04450173 | Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | ||
NCT01236391 | Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | ||
NCT03359460 | Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome | ||
NCT01969266 | A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food | ||
NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | ||
NCT01744691 | A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion | ||
NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | ||
NCT01779791 | A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma | ||
NCT01974440 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | ||
NCT01724346 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||
NCT02077166 | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | ||
NCT01752426 | Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL | ||
NCT03198026 | Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas | ||
NCT02902965 | Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma | ||
NCT02315326 | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | ||
NCT02966730 | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy | ||
NCT01109069 | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | ||
NCT00076401 | A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) | ||
NCT01325701 | Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | ||
NCT02959944 | Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) | ||
NCT02321540 | A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer | ||
NCT02643667 | Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer | ||
NCT00290004 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||
NCT00373204 | Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere) | ||
NCT03703167 | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | ||
NCT00129844 | Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer | ||
NCT02401048 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | ||
NCT00120939 | Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer | ||
NCT03702725 | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | ||
NCT02251548 | A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia | ||
NCT01292135 | Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) | ||
NCT02272686 | Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma | ||
NCT01543763 | Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors | ||
NCT04273139 | Ibrutinib + Venetoclax in Untreated WM | ||
NCT01833039 | An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | ||
NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | ||
NCT01704963 | A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms | ||
NCT00134186 | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer | ||
NCT00562224 | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients |